Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs is pleased to offer a range of CD83 CAR related products, such as CAR vector products, CAR viral particles, and CAR cells, tailored to meet your specific needs. Our products undergo stringent quality control procedures and leverage scientific expertise, guaranteeing dependable and consistent outcomes.
CD83 molecule plays a crucial role in coordinating appropriate immune responses and promoting the resolution of inflammation.
Fig.1 Human CD83-targeted chimeric antigen receptor T cells can be potentially used to prevent and treat GVHD.1
We offer a full range of CD83 proteins and custom cell products to detect the expression of CD83 CAR.
CD83 CAR-T Cytokine Release Test
Creative Biolabs has a team of highly skilled scientists and technicians who are experienced in performing the CD83 CAR-T cytokine release test, which is important in understanding the potential side effects and immune response of the therapy. The test helps to identify any excessive or abnormal cytokine release, which can indicate a possible cytokine release syndrome (CRS) or neurotoxicity.
Fig.2 Analysis of IFNγ and IL-2 released by CD83 CAR T cells after stimulation.1
CD83 CAR-T In Vitro Cytotoxicity Assay
At our state-of-the-art laboratory, we utilize cutting-edge techniques to evaluate the cytotoxic potential of CD83 CAR-T cells in an in vitro setting. The CD83 protein, expressed on dendritic cells, plays a critical role in immune regulation and activation. Our assay allows for the accurate assessment of the potency and efficacy of CD83 CAR-T cells in killing target cells.
Fig.3 Measurement of the cytotoxicity of CD83 CAR T cells.1
CD83 CAR-T Cell Proliferation Test
The CD83 CAR-T cell proliferation test is a vital component for the evaluation of CAR-T cell therapies. This test allows for an in-depth assessment of the proliferative capacity of CD83-driven CAR-T cells, ensuring their optimal functionality and effectiveness.
Fig.4 Proliferation analysis of CD83 CAR T cells.1
CD83 CAR-T Cell Therapy Animal Models
Our team of experienced scientists and researchers have developed robust and reliable animal models for CD83 CAR-T cell therapy studies. Our animal models are meticulously designed to accurately mimic the human immune system response to CD83 CAR-T cell therapy. We have accumulated extensive experience in engineering animal models with the stable and durable expression of the CD83 CAR construct.
Fig. 5 Human CD83 CAR T cells prevent xenogeneic GVHD.1
At our state-of-the-art testing facility, we have a team of highly skilled scientists and technicians who specialize in conducting comprehensive efficacy tests for CD83 CAR-T cells. Our rigorous testing protocols are designed to evaluate the potency and effectiveness of CD83 CAR-T cells in battling cancer cells.
Fig. 6 Human CD83-targeted CAR T cells significantly reduce CD83+ DCs.1
Toxicity Evaluation of CD83 CAR-T
Our specialized team of experts is skilled in evaluating the toxicity of CD83 CAR-T cells. We perform a series of comprehensive assays to determine any off-target effects.
Creative Biolabs is dedicated to delivering accurate and reliable results, ensuring that our clients receive the highest standard of service.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-0120ZP2953 | Anti-CD83 (2I5c) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2I5c | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2954 | Anti-CD83 (2I5c) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 2I5c | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2987 | Anti-CD83 (UCH-B1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | UCH-B1 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2988 | Anti-CD83 (UCH-B1) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | UCH-B1 | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2989 | Anti-CD83 (Michel17) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Michel17 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2990 | Anti-CD83 (Michel17) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Michel17 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2991 | Anti-CD83 (Michel-19) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Michel-19 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2992 | Anti-CD83 (Michel-19) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Michel-19 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2993 | Anti-CD83 (HB15) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HB15 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2994 | Anti-CD83 (HB15) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | HB15 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2995 | Anti-CD83 (5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 5 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2996 | Anti-CD83 (5) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 5 | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2997 | Anti-CD83 (3D11) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3D11 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2998 | Anti-CD83 (3D11) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 3D11 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2999 | Anti-CD83 (7H190) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7H190 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP3000 | Anti-CD83 (7H190) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 7H190 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP3001 | Anti-CD83 (6H4G10) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6H4G10 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP3002 | Anti-CD83 (6H4G10) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 6H4G10 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP3003 | Anti-CD83 (6D287) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6D287 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP3004 | Anti-CD83 (6D287) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 6D287 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
